advertisement
Amid the buzz around weight loss drugs and rising rates of obesity worldwide, many health care professionals are questioning one of the key measures that has long been used to define obesity.
On 14 June 2023, the American Medical Association adopted a new policy, calling on doctors to de-emphasise the role of body mass index, or BMI, in clinical practice.
As a board-certified obesity medicine physician with a research interest in patient-centered obesity care, I have written before about my concerns over the use of BMI as a measure of health.
The AMA’s policy statement creates an important opportunity to review the current use of BMI in health care settings and to consider what the future holds for the assessment of the health risks of elevated body weight.
Body mass index is a measurement taken by dividing body weight in kilograms by height in meters squared. The metric was developed to estimate a normal body weight depending on an individual’s height, given that taller people tend to weigh more.
It rose to prominence for clinicians in the 1990s following the World Health Organization’s adoption of the metric as the official screening index for obesity.
Because of that ample body of evidence from previous decades, one of the long-standing assumptions in the use of BMI as a measure of general health is that it accurately predicts an individual's body fat percentage and, therefore, the potential health risks of elevated weight.
However, while BMI may have strong correlations with the amount of body weight composed of body fat in studies of averages of large groups of people, it does not directly measure body fat for an individual.
In an example from one large study, adults with a BMI of 25 had a body fat percentage ranging from 14 to 35 percent for men and 26 to 42 percent for women.
Ultimately, BMI cannot provide doctors with precise information about the portion of body weight comprised of body fat, nor can it tell us how that fat is distributed in the body.
But this distribution is important because research has shown that fat stored around the internal organs has significantly higher health risks than that distributed in the extremities.
Further, just as a variety of health factors may affect the accuracy of BMI to predict how much body fat someone has, health outcomes such as developing diabetes at a specific BMI can vary substantially based on factors such as a person’s race, sex, age, and physical fitness level.
Although research in the 1970s suggested that any BMI above a normal (18.5-24.9) range shortened life expectancy, some modern studies suggest that BMI in the overweight (25-29.9) to class 1 obesity (30-34.9) range does not raise the risk of early death.
The potentially lower risk of death in modern studies for people with higher body weight might be explained by improved treatment of conditions such as high cholesterol and blood pressure, common contributors to shortened life expectancy for people with a BMI over 30.
Clinicians commonly use BMI as the metric to decide whether to recommend weight loss, drawing from recommendations such as those released by the United States Preventive Services Task Force, an independent, national panel of health care experts that writes guidelines on preventive health.
Its members cite the potential for lifestyle-based weight loss interventions to reduce obesity-related health risks as justification for the recommendation.
However, in their 2018 evidence review for these guidelines, task force researchers found no significant improvements in cardiovascular events, mortality or health-related quality of life in studies comparing those who received a lifestyle-based or medication-based weight loss intervention, or both, versus those who did not.
The only specific health outcome that was prevented was developing diabetes.
Whether newer, more effective weight loss medications, such as Ozempic, will lead to long-term health benefits remains to be seen.
Part of the reason that the evidence for health benefits of weight loss interventions is so poor is that body weight is regulated by a complicated hormonal system.
As a result, even in the optimal setting of clinical trials, the task force found that only 1 in 8 adults would sustain clinically meaningful weight loss of at least 5 percent of their prior body weight.
With the shift away from BMI, the AMA recommends alternative measures that clinicians can use for the assessment of the health risks of elevated body weight. A variety of measures are suggested, including body adiposity index, relative fat mass, waist-to-hip ratio, and waist circumference.
These measures attempt to better characterise fat distribution in the body, given the increased health risks of fat stored around the internal organs. They require additional measurements in a clinic visit.
In acknowledging the limitations in using BMI as a general measure of health or as a tool to assess the need for obesity treatment, the AMA has taken an important step toward diminishing the role of BMI in clinical practice. Further research is needed to identify the best ways to assess the health risks of elevated body weight.
(Scott Hagan is an Assistant Professor of Medicine, at School of Medicine, University of Washington. This article was originally published on The Conversation. Read the original article here.)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)
Published: undefined